SCHEMBL4619428

SCHEMBL4619428

Cc1cccc(C(O)(C(=O)NCC2C3CN(Cc4ccccc4)CC23)c2cccc(C)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.46
CHRM1 P11229 3/20 0.46
CHRM3 P20309 3/20 0.46
LMNA P02545 1/20 0.45
FAAH O00519 1/20 0.42
DCUN1D1 Q96GG9 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.39
BACE1 P56817 1/20 0.39
S1PR1 P21453 1/20 0.39
GRK5 P34947 1/20 0.39
CDK8 P49336 1/20 0.39
S1PR5 Q9H228 1/20 0.39
CCR2 P41597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128643 0.99 CHRM3 (0.45) CHRM2CHRM1CHRM3LMNAFAAH
SCHEMBL5093162 0.99 CHRM3 (0.45) CHRM2CHRM1CHRM3LMNAFAAH
SCHEMBL4143237 0.94 CHRM2 (0.50) CHRM2CHRM1CHRM3LMNAFAAH
SCHEMBL4143233 0.94 CHRM2 (0.50) CHRM2CHRM1CHRM3LMNAFAAH
SCHEMBL4189233 0.90 CHRM2 (0.46) CHRM2CHRM1CHRM3LMNAFAAH
SCHEMBL4136290 0.89 CHRM3 (0.45) CHRM2CHRM1CHRM3FAAHALDH1A1
SCHEMBL5099505 0.89 CHRM3 (0.45) CHRM2CHRM1CHRM3FAAHALDH1A1
SCHEMBL5105573 0.89 CHRM3 (0.46) CHRM2CHRM1CHRM3S1PR1S1PR5
SCHEMBL5105568 0.89 CHRM3 (0.46) CHRM2CHRM1CHRM3S1PR1S1PR5
SCHEMBL4137086 0.88 CHRM2 (0.48) CHRM2CHRM1CHRM3LMNAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US claimed
EP-1888525-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-02-20 EP claimed
WO-2006117754-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO claimed
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US disclosed
EP-1888525-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-02-20 EP disclosed
WO-2006117754-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 CHRM2 3/4885CHRM1 5/4885CHRM3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.